Abstract
Seasonal influenza causes a substantial public health burden, as well as being a key substrate for pandemic emergence. Future climatic and demographic changes may alter both the magnitude, frequency and timing of influenza epidemics and the prospects for pathogen evolution, however, these issues have not been addressed systematically. Here, we use a parsimonious influenza model, grounded in theoretical understanding of the link between climate, demography and transmission to project future changes globally. We find that climate change generally acts to reduce the intensity of influenza epidemics as specific humidity increases. However, this reduction in intensity is accompanied by increased seasonal epidemic persistence with latitude, which may increase suitability for year-round local influenza evolution. Using a range of population growth scenarios, we find that the number of global locations with high evolution suitability may double by 2050. High population growth in tropical Africa could thus make this region a locus of novel strain emergence, shifting the current focus from South East Asia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the Cooperative Institute for Modeling the Earth System (CIMES) (REB), US National Institutes of Health grant GM110748 (JS), Natural Sciences and Engineering Research Council (NSERC) of Canada (PGS-D to CMSR), the James S. McDonnell Foundation 21st Century Science Initiative Collaborative Award in Understanding Dynamic and Multi-scale Systems (CMSR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n/a
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is publicly available. Code available at https://github.com/rebaker64/flu.
